|
| Study type | No. of patients/lesions | SBRT target | SBRT regimen | Local control | OS | AE (≥Grade 3) | Ref |
|
| Retrospective study | 50 lesions | Bone metastasis | Most common is 27 Gy/3f | Rates at 12 and 24 months were both 74.9% | NA | Grade 3 AE: 1 patient, dermatitis | Amini et al. [35] |
| Retrospective study | 36 lesions | Thoracic, abdominal, and soft-tissue lesions | Most common is 50 Gy/5f | Rates at 12, 24, and 36 months were 100%, 93.41%, and 93.41%, respectively | Median OS about 32 months | Grade 3 AE: 1 patient, mucositis | Altoos et al. [36] |
| Retrospective study | 27 pts/37 lesions | Lung metastasis | Median SBRT dose and fraction were 50 Gy (range 25–60) and 3 (range 1–6) | 92.3% for median follow-up 16 months | NA | 0 | Altoos et al. [37] |
| Retrospective study | 57 pts/88 lesions | Spinal metastases | Single fraction, median 15 Gy | Median 26 months | 8.3 months (1.5–38) | 0 | Balagamwala et al. [38] |
| Prospective phase I trial | 12 pts | Primary renal lesions | 25 Gy, 30 Gy, or 35 Gy in 5 fractions | NA | 6.7 months (1.5–16.4) | Grade 3 AE: 3 patients, fatigue (2) and bone pain (1) | Correa et al. [39] |
| Retrospective study | 9 pts | Bilateral primary renal lesions | 60–85 Gy was delivered at 5–7 Gy/fraction | Rates at 1, 3, and 5 years were 64.8, 43.2, and 43.2%, respectively | Rates at 1, 3, and 5 years were 66.7, 53.3, and 35.6%, respectively | 0 | Wang et al. [40] |
| Prospective phase I trial | 15 pts | Primary renal lesions | 24–48 Gy/4f | 100% for median follow-up 13.67 months | Estimated 3-year OS post-treatment was 72%, 95% CI (0.44–0.87) | Grade 4 AE: 1 patient (5.3%) with duodenal ulcer possibly treatment-related | Ponsky et al. [41] |
| Prospective study | 37 pts | Primary renal lesions | 26 Gy/1f for tumors <5 cm and 42 Gy/3f for tumors ≥5 cm | Rates at 2 years was 100% | Rates at 2 years were 92% | Grade 3 AE: 1 patient (3%). | Siva et al. [42] |
| Retrospective study | 21 pts | Primary renal lesions | 48 Gy/3f | Rates at 1 year and 2 years were 92 and 84%, respectively | Rates at 1 year and 2 years were both 95% | 0 | Kaplan et al. [43] |
| Retrospective study | 32 pts/52 lesions | Brain metastasis | 22.0 Gy (range, 12.8–24.0 Gy) | NA | 6.3 months (0.4–100.4 months) | NA | Shah et al. [44] |
| Retrospective study | 16 pts/99 lesions | Brain metastasis (≥5) | SRS | 91% of targets | 50% after 6 months and 31% after 1 year | NA | Mohammadi et al. [45] |
| Retrospective study | 81 pts/117 lesions | Brain metastasis (from melanoma or renal cancer) | 18 Gy (range 15–20 Gy) | Rate at 1 year was 79.4% for renal cancer | Rates at 6 months and 1 year were 55.4% and 30.2%, respectively | NA | Feng and Lemons et al. |
| Retrospective study | 15 pts | Brain metastasis | SRS | NA | 8.4 months | NA | Feng et al. [46] |
| Retrospective study | 18 pts/39 lesions | Oligometastatic renal cancer (extracranial) | 8–14 Gy 3 fractions or 4–5 Gy 10 fractions | Rate at 2 years was 91.4% | 2 years was 85% | NA | Ranck et al. [47] |
| Retrospective study | 84 pts/175 lesions | Extracranial metastasis | (40–60 Gy/5f or 30–54 Gy/3f or 20-40 Gy/1f | 1-year LC rate was 91.2% | NA | Grade 3 events: 8 patients (4.6%). | Wang et al. [48] |
| Retrospective study | 48 patients/70 lesions | Spinal metastases | NA | Rate at 21 months was 72% | 66 months (CI95% 54–79) | NA | Serrand et al. [49] |
|
